Oiling the Brain: A Review of Randomized Controlled Trials of Omega-3 Fatty Acids in Psychopathology across the Lifespan by Sinn, Natalie et al.
 
Nutrients 2010, 2, 128-170; doi:10.3390/nu2020128 
 
nutrients 
ISSN 2072-6643 
www.mdpi.com/journal/nutrients 
Review 
Oiling the Brain: A Review of Randomized Controlled Trials of 
Omega-3 Fatty Acids in Psychopathology across the Lifespan 
Natalie Sinn *, Catherine Milte and Peter R. C. Howe  
 
Nutritional Physiology Research Centre, Sansom Institute for Health Research, University of South 
Australia, Frome Road, Adelaide 5000, Australia; E-Mails: catherine.milte@unisa.edu.au (C.M.); 
peter.howe@unisa.edu.au (P.H.) 
 
*  Author to whom correspondence should be addressed; E-Mail: natalie.sinn@unisa.edu.au. 
Received: 3 December 2009 / Accepted: 3 February 2010 / Published: 9 February 2010 
 
Abstract: Around one in four people suffer from mental illness at some stage in their 
lifetime. There is increasing awareness of the importance of nutrition, particularly omega-3 
polyunsaturated fatty acids (n-3 PUFA), for optimal brain development and function. 
Hence in recent decades, researchers have explored effects of n-3 PUFA on mental health 
problems over the lifespan, from developmental disorders in childhood, to depression, 
aggression, and schizophrenia in adulthood, and cognitive decline, dementia and 
Alzheimer’s disease in late adulthood. This review provides an updated overview of the 
published and the registered clinical trials that investigate effects of n-3 PUFA 
supplementation on mental health and behavior, highlighting methodological differences 
and issues. 
 
Keywords:  omega-3 polyunsaturated fatty acids; mental health; attention deficit 
hyperactivity disorder; autism; aggression; depression; dementia  
 
1. Introduction  
Mental health is described as “a state of well-being in which every individual realizes his or her 
own potential, can cope with the normal stresses of life, can work productively and fruitfully, and is 
able to make a contribution to her or his community” [1]. About 450 million people worldwide do not 
enjoy this state of wellbeing, and it is estimated that one in four people will suffer from mental illness 
at some stage in their lifetime, causing enormous suffering, personal, social and financial burden, as 
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well as associated physical illness [2]. Identification of preventable risk factors and effective 
treatments therefore constitutes an international priority. 
Nutrition has an important role in mental health as the brain relies on both macro- and 
micronutrients for development and functioning [3-6]. In particular, suboptimal levels of omega-3 
polyunsaturated fatty acids (n-3 PUFA) are emerging as a potentially modifiable risk factor for mental 
illness. Since their discovery in the 1970s as key components of brain tissue [7], long-chain n-3 PUFA 
have been postulated to serve critical roles in brain development, and function and a lack of these fatty 
acids has been implicated in a number of mental health conditions over the lifespan, from 
developmental disorders and mental retardation in childhood, to depression, bipolar disorder, 
schizophrenia and borderline personality disorder, stress, hostility and aggression in adulthood, and 
cognitive decline, dementia and Alzheimer’s disease in late adulthood [8].  
Although the etiology of these disorders is clearly multifactorial and subject to individual variation, 
the number of clinical trials addressing suboptimal n-3 PUFA levels as a possible underlying 
biological contributor to associated symptoms, and importantly symptoms that often co-occur and 
overlap between these disorders, is steadily growing. Following an overview of n-3 PUFA, we will 
provide a review of randomized controlled trials [8], and an update of recent trials located via the 
World Health Organization’s International Clinical Trials Registry Platform Search Portal [9], 
including preliminary results from our own recent studies, focusing on the role of n-3 PUFA in 
alleviating symptoms of psychopathology from childhood throughout adulthood. Trial identification 
numbers of registered trials not included in the original review were searched on PubMed to check if 
they had been published. Published and registered trials are summarized in Tables 1 and 2, 
respectively. 
2. Omega-3 PUFA  
2.1. Overview 
The omega-6 (n-6) and n-3 families of PUFA have numerous biological roles in cellular structure 
and function. Alpha linolenic acid (ALA; 18:3n-3), parent n-3 PUFA, and linoleic acid (LA; 18:2n-6), 
parent n-6 PUFA, cannot be synthesized by humans and must be provided via the diet. They are 
therefore termed essential fatty acids (EFA). Humans can obtain ALA in their diet via plant sources. 
EFA have 18 carbon atoms with double carbon bonds. These chains undergo further processes of 
elongation and de-saturation (insertion of additional double bonds) to form highly unsaturated long 
chain (LC) PUFA. Our bodies can perform these conversions, although not always very efficiently. 
Long chain (LC) derivatives of ALA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
are made by phytoplankton and transferred via the food-chain to marine organisms, particularly cold-
water fish and marine animals. Therefore, humans can also obtain these elongated n-3 PUFA directly 
via algal or fish sources.  
Structurally, PUFA are key components of phospholipids, comprising cellular and intracellular 
membranes. They govern growth and vitality through oxidation (metabolism of food to produce energy 
required for cellular processes), chemical activities and transportation. As well as constructing 
membranes and generating and propagating electrical impulses, LC-PUFA are required for synthesis of Nutrients 2010, 2                                       
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eicosanoids, important signaling hormones with numerous complex functions. Those derived from n-3 
LC-PUFA are generally anti-inflammatory, anti-thrombotic and vasodilatory, balancing and 
counteracting pro-inflammatory, vasoconstrictor actions of eicosanoids derived from n-6 LC PUFA [10]. 
The cardiovascular benefits of n-3 PUFA [11] are largely attributed to these eicosanoid properties, and 
they may also have important roles in brain function. 
2.2. Omega-3 PUFA and the Brain  
Lipids constitute approximately sixty percent of the dry weight of the brain. DHA and AA are the 
most highly concentrated PUFA in neural phospholipids, including subcellular membranes [12-14]. 
Although the circulation contains at least 10 times more n-6 than n-3 PUFA, DHA predominates in the 
retina, brain and nervous system [14]. Furthermore, DHA is particularly concentrated at neural 
synapses [15-19]. 
Importantly, DHA levels in neural membranes vary according to dietary oil intake [4,19,20] and 
there is evidence that low PUFA and high cholesterol levels reduce phospholipid fluidity [19,20]. 
Animal studies and human infant autopsies have also shown that when insufficient n-3 PUFA are 
available during early neural development, there is a decrease in the DHA content of the brain. 
Furthermore, increased n-6 to n-3 PUFA ratios can also alter the fatty acid composition of neural 
membranes [21].  
Various reviews have outlined biological mechanisms for n-3 PUFA in brain function [22-24]. In 
particular, and in line with a longstanding focus on the role of neurotransmitters such as dopamine and 
serotonin in mental illness, research has focused on associations between PUFA and central nervous 
system activity [25]. Evidence points to the role of eicosanoids in healthy brain functioning, and 
phospholipid membranes in neural cell signaling [12,19,26,27]. Levels of n-3 PUFA have been 
associated with monoaminergic neurotransmitter levels [27-30]. n-3 deficiency has also been found, in 
animal studies, to reduce levels of phosphatidylserine (PS) in the brain, which is thought to play an 
important function in neural signaling activities [12]. In alcoholics, DHA deficiency has predicted 
reduced 5-hydroxyindoleacetic acid (5-HIAA) concentrations in cerebrospinal fluid, an indicator of 
low serotonin turnover rate in the frontal cortex [31].  
Studies have further indicated that n-3 PUFA may affect receptor properties or activation of signal 
transduction by receptors [30]. Electrical impulse conduction is dependent on the exchange of ions 
through the cell membrane, which relies on the fluidity and physiological structure of cell membranes. 
Furthermore, there are indications that PUFA are involved in the synthesis and activities of brain 
peptides [19], which are involved in modulating the activities of neurotransmitters [32]. n-3 PUFA are 
also thought to influence gene expression of a range of enzymes required for important neural 
functions including synaptic transduction, ion channel formation, energy metabolism and formulation 
of proteins vital for brain development and function [22].  
Regular delivery of oxygen and nutrients via the blood is also critical for optimal brain function, 
and psychopathology is associated with both reduced cerebral blood flow and transportation of 
glucose, the brain’s primary energy source, to brain regions as required. In this regard, n-3 PUFA are 
associated with production of nitric oxide [33], as well as anti-inflammatory and vasodilatory 
eicosanoids (notably PGI2), and are known to assist in endothelial-dependent vasodilation [10]. They Nutrients 2010, 2                                       
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have also been associated with substantially increased transport of glucose across the blood-brain 
barrier [34,35]. Therefore, it is also possible that their primary influence on brain function includes 
improved cerebral blood flow and blood-brain barrier integrity [36]. This notion is supported by the 
high co-morbidity between cardiovascular disease and psychopathology, indicative of a common 
underlying vascular pathology that may be mediated by lifestyle factors such as suboptimal levels of n-
3 PUFA [37]. 
A review of controlled animal studies [30] concluded that there is sufficient evidence of a role for n-
3 PUFA in improving learning and behavior. A large body of research has investigated n-3 PUFA in 
infant development, which is also reviewed elsewhere [38]. The present review will focus on mental 
health problems in childhood through to late adulthood. 
3. PUFA and Mental Illness 
PUFA deficiencies have been reported in people with a range of psychiatric problems [22-24,39-41], 
including developmental disorders such as attention deficit hyperactivity disorder (ADHD), 
depression, bipolar disorder, stress, aggression, hostility and criminality, and dementia. A small but 
growing body of clinical research trials has been conducted with variable outcomes. These will be 
reviewed here, and are summarized in Table 1. 
Table 1. Double-blind randomized placebo-controlled trials of omega-3 fatty acids in 
mental illness. 
Authors  Participants   Daily dosage  Length of 
trial 
Measures Outcomes*   
Voigt et al. 
(2001) [53] 
N = 54; 6-12 year old 
(78% boys); idiopathic 
ADHD diagnosis; were 
being treated successfully 
with medication 
345 mg DHA 
(algae-derived) 
or undefined 
placebo 
16 weeks  CPRS; CBC; 
TOVA; CCT 
Treatment = placebo on all 
measures 
Stevens et 
al. (2003) 
[59] 
N = 50; 6-13 year old 
(78% boys); ADHD 
diagnosis; high FADS
l; 
some on medication 
(equally allocated to 
conditions) 
96 mg GLA, 40 
mg AA, 80 mg 
EPA, 480 mg 
DHA, 24 mg 
Vit E or olive 
oil placebo 
16 weeks  DBD; ASQ; 
CPT; 
WJPEB-R; 
FADS 
Treatment > placebo: 
DBD-Conduct (parents); 
DBD-Attention (teachers). 
Other 14 outcome 
measures non-significant 
Hirayama et 
al. (2004) 
[55] 
N = 40; 6-12 year old 
(80% boys); ADHD 
diagnosis; 15% medicated; 
82% comorbid conditions 
100 mg EPA, 
514 mg DHA 
or olive oil 
placebo 
(supplied in 
soymilk & 
bread) 
8 weeks  ADHD 
DSM-IV; 
DTVP; STM; 
CPT; Other 
Treatment = placebo on all 
measures (except that 
placebo > treatment on 
CPT and STM) Nutrients 2010, 2                                       
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Table 1. Cont. 
Richardson 
& Puri 
(2002) [58] 
N = 29; 8-12 year old 
(62% boys); normal IQ; 
low reading ability; above 
average ADHD scores on 
Conners’ Index; no 
participants in treatment 
for ADHD 
864 mg LA, 42 
mg AA, 96 mg 
ALA, 186 mg 
EPA, 480 mg 
DHA, 60 iµ Vit 
E or olive oil 
placebo  
12 weeks  CPRS  Treatment > placebo: 
CPRS; Cognitive 
problems/inattention; 
Anxious/shy; Conners’ 
global index; DSM 
inattention; DSM 
hyperactive/impulsive; 
Conners’ ADHD Index 
Richardson 
& 
Montgomery 
(2005) [60] 
N = 117; 5-12 year old 
(77% boys); 
Developmental 
Coordination Disorder, 1/3 
with ADHD symptoms in 
clinical range, not in 
treatment; IQ > 70;  
60 mg AA, 10 
mg GLA, 558 
mg EPA, 174 
mg DHA, 9.6 
mg Vit E or 
olive oil 
placebo 
12 weeks 
active vs. 
placebo; 
one-way 
crossover 
to active 
treatment 
for 12 
weeks 
MABC; 
WORD; 
CTRS 
Treatment > placebo: 
WORD; CTRS 
Oppositional behaviour; 
Cognitive 
problems/inattention; 
Hyperactivity; 
Anxious/shy; 
Perfectionism; Social 
problems; Conners’ index; 
DSM-IV inattention, 
hyperactive/impulsive 
Treatment = placebo: 
MABC 
Sinn et al. 
(2007; 2008) 
[61,62]
  
N = 132 (questionnaire 
data available for 104); 7-
12 year old (74% boys); 
ADHD symptoms in 
clinical range; 
unmedicated 
60 mg AA, 10 
mg GLA, 558 
mg EPA, 174 
mg DHA, 9.6 
mg Vit E, or 
palm oil 
placebo 
15 weeks 
active vs. 
placebo; 
one-way 
crossover 
to active 
treatment 
for 15 
weeks 
CPRS, CTRS 
Vocabulary, 
subtests from 
WISC-III & 
TEA-ch, 
Stroop 
Treatment > placebo 
CPRS: Cognitive 
problems/inattention; 
Hyperactivity; ADHD 
Index; Restless/Impulsive; 
DSM-IV 
Hyperactive/Impulsive; 
Oppositional. Treatment = 
placebo on other subscales 
and CTRS.  
Treatment > placebo on 
Creature Counting & 
vocabulary. Treatment = 
placebo on other cognitive 
tests Nutrients 2010, 2                                       
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Table 1. Cont. 
Johnson et 
al. (2008) 
[64] 
N = 75, 8-18 year old 
children with diagnosed 
ADHD, unmedicated 
(85% males) 
60 mg AA, 10 
mg GLA, 558 
mg EPA, 174 
mg DHA, 9.6 
mg Vit E or 
olive oil 
placebo 
3 months 
active vs. 
placebo; 
one-way 
crossover 
to active 
treatment 
for 3 
months 
Investigator-
rated ADHD 
Rating Scale-
IV; CGI 
Treatment = placebo 
overall 
Treatment > placebo in 
subgroups with inattentive 
subtype & comorbid 
neurodevelopmental 
disorders 
Milte et al. 
(in 
preparation) 
[65]  
N = 54 (45 with bloods), 
7-12 year old (79% male) 
with ADHD/ADHD 
symptoms (50% 
diagnosed) 
ACTRN012607000332426 
1g EPA-rich 
oil, 1g DHA 
rich oil or 
sunflower oil 
placebo 
3 x 3 
crossover 
(4 months 
on each 
treatment) 
CPRS, 
reading, 
writing, 
vocabulary, 
TEA-ch 
Treatment = placebo in 12-
month crossover. 
Over 4 months erythrocyte 
DHA increases associated 
with improvements on 
CPRS - oppositional 
behaviour, anxiety/shyness 
– divided attention & 
reading. In subgroup with 
learning difficulties (n = 16 
with blood) also on CPRS 
hyperactivity/impulsivity 
and spelling. 
Amminger 
et al. (2007) 
[80] 
N = 13 (5-17 years) with 
Autistic Disorder (81.9% 
male) 
1.5g/d n-3 
PUFA (0.84g 
EPA, 0.7g 
DHA), Vit E ; 
or coconut oil 
placebo  
6 weeks 
parallel 
design 
Aberrant 
Behavior 
Checklist 
(ABC) 
Treatment > placebo for 
stereotypy & hyperactivity 
(trends with large effect 
sizes) 
Treatment = placebo on 3 
other subscales 
Peet & 
Horrobin 
(2002)  
[103] 
N = 70 (18-70 years), 
depressed (>15 on HDRS), 
medicated 
Ethyl-EPA – 1, 
2 or 4 g/day or 
placebo 
12 week 
parallel 
design, 
adjunctive 
therapy 
HDRS, 
MADRS, 
BDI 
Treatment > placebo on all 
3 rating scales with 1g/day 
EPA – strong effects for 
core depressive symptoms. 
Treatment = placebo on 2g 
and 4g/day (non-significant 
trends) 
Nemets et 
al. (2002) 
[104] 
N = 20 (28-73 years), 
diagnosed major 
depression disorder (85% 
women) HDRS score > 18 
2g ethyl-EPA 
(96% from fish 
oil) or placebo, 
Vit E 
4 weeks 
parallel 
design, 
adjunctive 
therapy 
HDRS  Treatment > placebo at 
weeks 2, 3 and 4 on HDRS 
score and on core 
depressive symptom 
subscales. Nutrients 2010, 2                                       
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Su et al. 
(2003) [106] 
N = 22 (18-60 years), 
outpatients with major 
depressive disorder; 
HDRS score > 18, 
medicated 
3.3g/day n-3 
PUFA (2.2g 
DHA, 1.1g 
EPA) 
8 weeks 
parallel 
design, 
adjunctive 
therapy 
HDRS  Treatment > placebo on 
HDRS 
Marangell et 
al. (2003) 
[111] 
N = 35 (18-65 years), 
major depressive disorder 
diagnosis; HDRS score > 
16 (80% female) 
2g/day DHA or 
placebo 
6 weeks 
parallel 
MADRS, 
HDRS, 
GAFS 
Treatment = placebo on 
outcome measures 
Silvers et al. 
(2005) [112] 
N  =77 (18-65 yrs 
recruited, mean age 38), 
being treated for current 
depressive episode (53% 
female) 
3g/day n-3 
PUFA (2.4g 
DHA ; 0.6g 
EPA) + Vit 
E  or olive oil 
placebo 
12 weeks 
parallel, 
adjunctive 
therapy 
HDRS short 
form, BDI 
Treatment = placebo on 
outcome measures 
(improvements in both 
groups at week 2) 
Nemets et 
al. (2006) 
[105] 
N  = 20 (6-12 year old; 
25% girls); children with 
major depressive disorder 
400mg EPA + 
200mg 
DHA/day or 
safflower 
oil/olive oil 
placebos 
16 weeks, 
parallel (5 
children 
medicated) 
aCDRS, CDI, 
CGI 
Treatment > placebo on 
outcome measures 
Grenyer et 
al. (2007) 
[113, 114] 
N = 83 (18-72 years, M = 
45), outpatients with major 
depression diagnosis 
3g/day n-3 
PUFA (2.2g 
DHA, 0.6g 
EPA) + Vit E 
or olive oil 
placebo 
4 month 
parallel 
design, 
adjunctive 
therapy 
HDRS, BDI, 
GAFS 
Treatment = placebo on 
outcome measures 
(improvements in both 
groups) 
Su et al. 
(2008) [109] 
N = 24 (18-40 years); with 
major depressive disorder 
during pregnancy 
2.2g EPA + 
1.2g DHA or 
placebo, both 
with 
tocopherols & 
orange flavor 
8 weeks, 
parallel 
design 
HDRS, 
EPDS, GDI 
Treatment > placebo on 
outcome measures Nutrients 2010, 2                                       
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Rogers et al. 
(2008) [117] 
N = 190 (18-70 years 
recruited, mean age = 38); 
people from GP surgeries 
or public with mild-
moderate depression (77% 
female) 
630mg EPA, 
850mg DHA, 
870mg olive 
oil, or olive oil 
placebo (both 
with 
tocopherols & 
orange oil) 
12 weeks 
parallel 
design 
DASS, BDI, 
STAEI, 
mood using 
diary and 
visual probe 
task, 
cognitive 
function 
Treatment = placebo on 
outcome measures 
(improvements in both 
groups) 
Van de Rest 
et al. (2008) 
[118]  
N = 302 (> 65 years, M = 
70; 55% male) non-
depressed community 
dwelling adults. 
NCT00124852 
1.8g/day EPA 
+ DHA, 
400mg/day 
EPA + DHA or 
placebo 
26 weeks 
parallel 
design 
CES-D, 
MADRS, 
GDS-15, 
HADQ, 
[POMS short 
form (n = 
104)] 
Treatment = placebo on 
outcome measures 
Freund-Levi 
et al. (2008) 
[115] 
N = 204 (mean age 73 
years); people with AD 
living in own homes, on 
stable treatment with 
acetylcholine esterase 
inhibitors. NCT00211159 
1.72g DHA + 
600mg 
EPA/day or 
corn oil 
placebo 
6 months 
parallel + 
one-way 
crossover 
to fish oil 
for 6 
months 
NPI, 
MADRS, 
CGB, DAD 
Treatment = placebo on 
outcome measures. 
Treatment > placebo on 
MADRS in non-apoE-4 
carriers and agitation in 
apoE-4 carriers 
Lucas et al. 
(2009) [108] 
N = 120 (recruited 40-55 
yrs; mean age 49) post-
menopausal women with 
psychological distress & 
depressive symptoms 
1.5g ethyl-
EPA, 0.5g 
ethyl-DHA 
8 weeks 
parallel 
design 
PGWB, 
HSCL-D-20, 
HDRS 
Treatment = placebo on all 
measures (improvements in 
both groups). Treatment > 
placebo in women without 
MDE (major depressive 
episode diagnosis) 
Carney et al. 
(2009) [116] 
N = 122; major depression 
+ coronary heart disease 
NCT00116857 
930mg ethyl-
EPA + 750mg 
ethyl DHA/day 
or corn oil 
placebo 
10 weeks 
parallel 
design, 
adjunctive 
therapy 
BDI-II; 
HDRS 
Treatment = placebo on 
outcome measures 
(improvements in both 
groups) 
Stoll et al. 
(1999) [120] 
N = 30 (18-65 years); 
inpatients with bipolar 
disorder 
9.6g/day n-3 
PUFA (6.2g 
EPA, 3.4g 
DHA) or olive 
oil esther 
placebo 
4 month 
parallel 
design; 
adjunctive 
therapy 
HDRS, 
YMRS, CGI-
S, GAS 
Treatment > placebo on 
GAS, HDRS and CGI; 
Treatment = placebo on 
YMRS Nutrients 2010, 2                                       
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Keck et al. 
(2006) [123] 
N = 116 (n= 57 bipolar 
depressed; n = 59 rapid 
cycling), mean age: 45; 
51% male 
6g/day ethyl-
EPA or liquid 
paraffin 
placebo 
4 month 
parallel 
design; 
adjunctive 
therapy 
IDS, YMRS, 
CGI-BP 
(bipolar 
disorder) 
Treatment = placebo on 
outcome measures 
Frangou et 
al. (2006) 
[124] 
N = 75 (mean age: 47); 
outpatients with bipolar 
depression + scores > 17 
on HDRS (76% female) 
1g/day ethyl 
EPA (n = 24) ; 
2g/day ethyl 
EPA (n = 25) 
or paraffin 
placebo 
12 week 
parallel 
design, 
adjunctive 
therapy 
HDRS, 
YMRS, CGI 
Treatment > placebo on 
HDRS & CGI on 1g and 
2g/day. Treatment = 
placebo on YMRS 
Hallahan et 
al. (2007) 
[127]  
N = 49 (16-64 years, M = 
30); presenting after act of 
repeated self-harm (65% 
women) 
1.2g/day EPA 
+ 0.9g DHA or 
corn oil 
placebo (with 
1% EPA/DHA) 
12 weeks 
parallel 
design in 
addition to 
standard 
care 
BDI, HDRS, 
OAS-M, 
IMT/DMT, 
PSS, DHUS 
Treatment > placebo on 
BDI, HDRS, PSS, DHUS. 
Treatment = placebo on 
OAS-M & IMT/DMT 
(hostility/aggression, 
memory)  
Peet et al. 
(2001) [139] 
Study 1: N = 45 (mean 
age: 44 yrs); schizophrenic 
patients, PANSS score > 
40 
 
 
Study 2: N = 30 (mean age 
35 years); diagnosed 
schizophrenia, untreated 
2g EPA, 2g 
DHA or 
placebo 
 
 
 
2g/day EPA or 
corn oil 
placebo 
 
3 months 
parallel 
adjunctive 
therapy 
 
 
3 months 
parallel, 
single 
therapy 
unless 
drugs 
needed 
PANSS 
 
 
 
 
 
PANSS; need 
for 
antipsychotic 
medication 
EPA treatment > placebo 
or DHA on positive PANSS 
score. Treatment = placebo 
on negative symptoms 
score 
 
Treatment  > placebo, 
particularly on positive 
subscale; 12/12 placebo 
and 8/14 EPA patients took 
medication  
 
Fenton et al. 
(2001) [141] 
N = 87 (18-65 years, M = 
40; 61% male) diagnosed 
schizophrenia or 
schizoaffective disorder 
3g/day ethyl 
EPA + Vit E or 
mineral oil + 
Vit E placebo 
16 week 
parallel 
design, 
adjunctive 
therapy 
PANSS, 
CGI, 
MADRS, 
RBANS, 
AIMS, SARS 
Treatment = placebo on 
outcome measures (some 
showed improvements in 
both groups) 
Emsley et al. 
(2002) [138] 
N = 40 (18-55 years, M = 
45); schizophrenic, 
treatment resistant 
patients, PANSS score > 
10 
3g/day ethyl-
EPA or liquid 
paraffin 
placebo 
12 weeks 
parallel 
design, 
adjunctive 
therapy 
PANSS, 
ESRS 
Treatment > placebo on 
PANSS and dykinesia 
subscale of ESRS. 
Treatment = placebo on 
other ESRS subscales Nutrients 2010, 2                                       
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Peet & 
Horrobin 
(2002) [140] 
N = 115 (20-62 years, M = 
37; 66% male), treatment-
resistant schizophrenia; 
PANSS > 50 
1, 2 or 4g/day 
ethyl-EPA or 
liquid paraffin 
placebo 
12 weeks 
parallel 
design, 
adjunctive 
therapy 
PANSS, 
LUNSERS, 
MADRS, 
AIMS, BAS, 
SARS 
Treatment = placebo on all 
rating scales; 2g treatment 
> placebo for patients on 
clozapine (associated with 
↑AA) 
Berger et al. 
(2007) [144] 
N = 69 (mean age 21 ± 4; 
76% male) first episode 
psychosis patients 
2g/day ethyl-
EPA or mineral 
oil placebo not 
absorbed by 
intestinal tract 
(both with 
Vitamin E) 
12 weeks 
parallel 
design, 
adjunctive 
therapy  
BPRS, 
SANS, 
CDSS, CGI, 
GAF, 
SOFAS 
Treatment = placebo on all 
outcome measures. 
Treatment > placebo on 
CGI co-varying for 
duration of untreated 
psychosis; treatment > 
placebo at weeks 4-6 
Amminger 
et al. (2010) 
[145] 
N = 81 (13-25 years, M = 
16 ± 2, 40% male), met 
defined risk factors for 
psychosis 
      
Hamazaki et 
al. (1996) 
[147] 
N = 41 (19-30 years, 70% 
female); university 
students (study measured 
aggression and executive 
function) 
1.5-1.8g/day 
DHA or 97% 
soybean oil + 
3% fish oil 
placebo 
capsules 
3 months 
parallel 
design 
P-F Study; 
Stroop; 
Dementia-
detecting test 
Treatment > placebo on 
extragression (increased in 
placebo group during exam 
time); treatment = placebo 
on other measures 
Gesch et al. 
(2002) [150] 
N = 172 (male offenders > 
18 years); prison inmates  
Vitamin and 
mineral 
supplement + 
80mg EPA, 
44mg DHA, 
1.26g ALA or 
veg oil placebo 
20 weeks, 
parallel 
design 
No. 
disciplinary 
actions; 
GATB; ECQ; 
SAS; HADQ 
Treatment > placebo on 
OAS-M & MADRS 
Zanarini et 
al. (2003) 
[149] 
N = 30 (18-40 years; M = 
26); females with 
moderately severe 
borderline personality 
disorder 
1g/day ethyl-
EPA or mineral 
oil placebo 
8 weeks 
parallel 
design 
OAS-M; 
MADRS 
Treatment > placebo no. 
disciplinary actions 
Treatment = placebo on 
psychological measures Nutrients 2010, 2                                       
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Table 1. Cont. 
Bradbury et 
al. (2004) 
[148] 
Stressed university staff 
(PSS scores ≥ 17) 
ISRCTN22569553 
1.5g DHA + 
360mg EPA + 
Vit E, olive oil 
placebo, or no 
treatment 
control 
6 weeks 
parallel 
design 
PSS  Treatment = placebo on 
PSS; treatment > no 
treatment control 
Buydens-
Branchey et 
al. (2008) 
[156] 
N = 24 (mean age 51 
years); patients with 
history of aggression 
2.5g EPA + 
0.5g DHA/day 
+ Vit E or 
soybean oil + 
Vit E placebo 
3 months 
parallel 
design, 
most 
taking 
medication 
Anger score 
on POMS 
Treatment > placebo on 
POMS anger scores 
Yehuda et 
al. (1996) 
[168] 
N =100 (50-73 years; 21% 
females) AD patients 
0.5g ALA :LA, 
1 :4 ratio (n = 
60) or mineral 
oil placebo 
4 weeks 
parallel 
design, 
adjunctive 
therapy 
12-item 
quality of life 
questionnaire 
(caregiver), 
clinician 
interview 
Treatment > placebo on 
12-item QOL 
questionnaire.  
Clinician interviews not 
reported. 
Terano et al. 
(1999) [169] 
N = 20 (mean age 83) 
nursing home residents 
with mild-moderate 
vascular dementia 
4.32g/day 
DHA or 
‘control’ 
12 months 
parallel 
design 
MMSE; 
HDS-R; 
clinical 
evaluation 
Treatment > placebo on 
outcome measures after 3 
& 6 months, associated 
with DHA increases 
Kotani et al. 
(2006) [171] 
N = 21 (mean age 68; 57% 
male); outpatients with 
MCI 
 240mg/day 
AA+DHA or 
olive oil 
placebo 
3 months 
parallel 
design 
RBANS 
(Japanese 
version) 
Treatment > placebo on 
immediate memory & 
attention. Treatment = 
placebo on other 10 sub-
scales 
Freund-Levi 
et al. (2006) 
[172] 
N = 178 (mean age 74); 
mild-moderate AD 
patients NCT00211159 
1.72g DHA + 
600mg 
EPA/day or 
placebo 
6 months 
parallel 
design, 
adjunctive 
therapy 
MMSE, 
ADAS-cog; 
global 
function on 
bCDRS 
Treatment = placebo on 
outcome measures. 
Treatment > placebo on 
MMSE  in mild MCI group 
(n = 27) 
Chiu et al. 
(2008) [173] 
N = 35 (mean age 74; 57% 
female); AD or MCI 
1.08g EPA + 
.72g DHA or 
olive oil 
placebo 
6 months  CIBIC-plus; 
ADAS-cog; 
MMSE; 
HDRS 
Treatment > placebo on 
CIBIC-plus. Treatment = 
placebo on other measures. 
Treatment > placebo on 
ADAS-cog in MCI sub-
group   Nutrients 2010, 2                                       
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Table 1. Cont. 
van de Rest 
et al. (2008) 
[174] 
N = 302 (mean age 70 
years; 55% male) 
community non-demented 
dwelling adults NTR97; 
ISRCTN46249783 
1.8g/day 
EPA+DHA; 
400mg/day 
EPA + DHA; 
or sunflower 
oil placebo; 
tocopherol 
added 
26 weeks 
parallel 
design 
Word 
Learning 
Task; Digit 
Span; Trail 
Making; 
Stroop; 
Verbal 
Fluency 
Treatment = placebo on 
outcome measures; 
Treatment > placebo on 
attention for apoE-4 
carriers and males 
Note: Trials are grouped according to subheadings in main text (e.g., ADHD, depression, etc.) 
*Positive treatment effects are presented in italic. AD = Alzheimer’s Disease; ADAS-cog = 
cognitive portion of the Alzheimer’s Disease Assessment Scale; ADHD = attention deficit 
hyperactivity disorder; AIMS = Abnormal Involuntary Movement Scale; ASQ = Conners’ 
Abbreviated Symptom Questionnaires; BDI = Beck Depression Inventory; BPRS = Brief 
Psychiatric Rating Scale; CBC = Child Behavior Checklist; CCT = Children’s Color Trails test; 
CDI = Childhood Depression Inventory; 
aCDRS = Childhood Depression Rating Scale; 
bCDRS = 
Clinical Dementia Rating Scale; CDSS = Calgary Depression Scale for Schizophrenia; CES-D = 
Centre for Epidemiologic Studies Depression Scale; CGB = Caregivers Burden Scale; CGI-S = 
Clinical Global Impression-Severity; CIBIC-plus = Clinician’s Interview-Based Impression of 
Change Scale; CPRS = Conners’ Parent Rating Scales; CPT = Conners’ Continuous 
Performance Test; CTRS = Conners’ Teacher Rating Scales; DAD = Disability Assessment for 
Dementia scale; DASS = Depression & Anxiety Stress Scale; DBD = Disruptive Behavior 
Disorders rating scale; DHUS: Daily Hassles & Uplifts Scale; DMT: Delayed Memory Task; 
DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, version 4; DTVP = 
Development Test of Visual Perception; ECQ = Emotional Control Questionnaire; EPDS = 
Edinburgh Postnatal Depression Scale; ESRS = Extrapyramidal Symptom Rating Scale; FADS = 
fatty acid deficiency symptoms; GAFS = Global Assessment of Functioning Scale (revised 
GAS); GAS = Global Assessment Scale; GATB = General Aptitude Test Battery; GDS = 
Geriatric Depression Scale; HADQ = Hospital Anxiety & Depression Questionnaire; HDRS = 
Hamilton Depression Rating Scale; HSCL-D-20 = 20-item Hopkins Symptom Checklist 
Depression Scale; IDS = Inventory for Depressive Symptomology; IMT = Immediate Memory 
Task; LUNSERS = Liverpool University Neuroleptic Side-Effects Rating Scale; MABC = 
Movement Assessment Battery for Children; MADRS = Montgomery-Asberg Depression Rating 
Scale; MCI = Mild Cognitive Impairment; MMSE = Mini-Mental State Examination; NPI = 
Neuropsychiatric Inventory; OAS-M = The Overt Aggression Scale, Modified; PANSS = 
Positive and Negative Syndrome Scale; PGWB = Psychological General Well-Being Schedule; 
P-F Study: measures aggression, including extra- & intra-aggression; POMS = Profile of Mood 
States; PSS: Perceived Stress Scale; RBANS = Repeatable Battery for the Assessment of 
Neuropsychological Status; SANS = Scale for the Assessment of Negative Symptoms; SARS = 
Simpson-Angus Rating Scale; SAS = Survey Anger Scales; SOFAS = Social and Occupational 
Functioning Assessment Scale; STAEI = State-Trait Anger Expression Inventory; Stroop = Nutrients 2010, 2                                       
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Stroop color-word test; STM = Short-term memory; TEA-ch = Test of Everyday Attention for 
children; TOVA = Test of Variables of Attention; Vit E = Vitamin E (α-tocopheryl acetate); 
WISC-III = Wechsler Intelligence Scale for Children, version 3; WORD = Wechsler Objective 
Reading Dimensions; WJPEB-R = Woodstock-Johnston Psycho-Educational Battery – Revised; 
YMRS = Young Mania Rating Scale 
3.1. Attention Deficit Hyperactivity Disorder (ADHD) 
Increasing attention has been given to the role of EFA in childhood developmental disorders. Given 
that brain development continues throughout childhood [42,43], PUFA supplementation may also have 
a beneficial effect during developmental milestones, particularly in children with developmental 
disorders that might be related to problems with PUFA metabolism and/or deficiency.  
Since the 1980s, researchers have identified lower levels of n-3 and n-6 PUFA in blood analyses of 
hyperactive children compared with matched controls [44-51]. Therefore a growing number of clinical 
trials are investigating effects of PUFA supplementation on ADHD-related symptoms. 
Early intervention trials were reported to show little or no improvement in alleviating hyperactive 
symptoms of ADHD with evening primrose oil, which contains the n-6 PUFA GLA [44,52]. Following 
these studies and with increasing awareness of the importance of n-3 PUFA, 8 randomised, double-
blind, placebo-controlled PUFA supplementation trials have been completed with children displaying 
ADHD-related symptoms, with varying results. These could be attributed to methodological 
differences such as variations in dosage, PUFA formulation, period of supplementation, selection 
criteria and outcome measures. 
In the first study, supplementation with 345mg of DHA per day over four months in 6–12 year old 
children diagnosed with ADHD did not significantly improve objective or subjective measurements of 
symptoms, even though there was a significant increase in RBC levels of DHA in the DHA group [53]. 
In this study, stimulant medication ceased 24 hours before laboratory measurements. However, parents 
completed the subjective scales (Child Behavior Checklist and Conners’ Rating Scales) while the 
children were still receiving stimulant medication. This may have influenced the results by masking 
their symptoms and making it difficult to detect any improvements; closer inspection confirms that t-
scores on parent rating scales were in the normal range before supplementation. Moreover, children 
who had experienced ineffective treatment with stimulant medication or had a previous diagnosis of 
mood, anxiety, thought or bipolar disorder were excluded from the study. It is presumed that the 
rationale for this was to select a group of children with ‘pure’ ADHD symptoms. This may not be 
entirely practical due to the high co-morbidity prevalent in ADHD and, as discussed by Richardson [54], 
the heterogeneity of ADHD and its overlap with other neurodevelopmental disorders needs to be 
explored within a phospholipid framework. 
Another study using both DHA and EPA (supplemented in fish oil-enriched bread, supplying 
3600mg DHA and 700mg EPA per week, or 514mg DHA and 100mg EPA per day) [55] also found no 
significant treatment effects on ADHD symptoms, in a two month placebo-controlled, double-blind 
trial with 40 children aged 6-12 who were mostly drug-free (34/40). The placebo bread contained olive 
oil. Paradoxically, the control group had significant improvements in visual short-term memory and 
errors of commission that were not seen in the treatment group. Blood samples were not taken, so it is Nutrients 2010, 2                                       
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not clear whether this sample had low n-3 PUFA levels at baseline. Given that the study was 
conducted in Japan, known to have high fish consumption, it is likely that baseline levels were 
relatively high. It is also possible that two months may have been insufficient time for effects to 
become observable, as it may take longer to elevate the fatty acid composition of neural   
membranes [56,57].  
Five other interventions reported improvements in symptoms with a combination of n-6 and n-3 
PUFA, including both EPA and DHA. In a pilot study, 41 British children aged 8–12 years with 
ADHD-related symptoms and specific learning disabilities (dyslexia) were given a PUFA supplement 
or olive oil placebo over 12 weeks [58]. The PUFA supplement in this study provided a daily dose of 
186mg EPA, 480mg DHA, 864mg LA and 42mg AA, as well as α-tocopherol (Vitamin E). These 
children all had above average scores on parent ratings of ADHD symptoms, and average general 
ability yet low reading achievement. Baseline measures on learning and behaviour did not differ 
between the groups, but the PUFA group showed improvements on global ADHD indices and subscale 
ratings of cognitive problems/inattention, hyperactivity, restlessness/impulsivity, psychosomatic 
complaints and anxiety/shyness on Conners’ Parent Rating Scale following 12 weeks of 
supplementation, with medium effect sizes reported. 
Similarly, another study investigated effects of PUFA supplementation, providing a daily dose of 
80mg EPA, 480mg DHA, 40mg AA, 96g GLA and 24mg α-tocopherol, or olive oil placebo, over four 
months in American children with ADHD-like symptoms, selected for thirst and skin problems 
indicative of fatty acid deficiency [59]. Plasma proportions of DHA, EPA and α-tocopherol increased 
in the intervention group following supplementation and there was a significant drop in n-6 to n-3 
ratios, although the olive oil group demonstrated a small increase in ALA. Significant treatment effects 
were found for only 2 of 16 outcome measures when compared to placebo: parent ratings of conduct 
and teacher ratings of attention. Oppositional defiant behavior scores significantly improved from 
clinical to non-clinical levels, and significant relationships were reported between the change in RBC 
PUFA and the magnitude of improvements in outcome measures. Increased levels of EPA and DHA 
were associated with decreases in teacher ratings of inattention and increased levels of EPA with 
parent ratings of reduced disruptive behaviour. Methodological issues in this study included increased 
n-3 plasma levels in the placebo (olive oil) group and small sample size (N = 50 plus 17 dropouts).  
Two larger double-blind, placebo-controlled trials investigated effects of PUFA on ADHD 
symptoms. The first study [60] included 117 children diagnosed with dyspraxia, or Developmental 
Coordination Disorder (DCD), and a third of the sample had scores  2 SD above the population mean 
on the DSM-IV ADHD subscale of Conners’ Teacher Rating Scales (CTRS). The children were 
functioning on average about a year behind their chronological age in reading and spelling. The active 
supplement provided a high ratio of EPA:DHA with a daily dose of 552 mg EPA, 168 mg DHA, 60mg 
DGLA and 9.6 mg α-tocopherol. Although no improvements were detected on the core DCD symptom 
of poor motor function after three months, highly significant improvements were reported in reading 
and spelling in the treatment group compared to placebo over three months and significant treatment 
effects were observed for teacher ratings of oppositional behaviour, cognitive problems/inattention, 
hyperactivity, anxiety/shyness, and global/DSM-IV ADHD. Following a one-way, uncontrolled Nutrients 2010, 2                                       
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crossover to active treatment for a further three months, the placebo group demonstrated similar 
improvements in mean scores, while the original treatment group’s scores continued to improve.  
The second large intervention included 132 Australian children, all with ADHD symptoms > 90
th 
percentile and therefore in the clinical range for a diagnosis [61]. Children received the same treatment 
as above (a daily dose of 552 mg EPA, 168 mg DHA, 60mg DGLA and 9.6 mg α-tocopherol) with or 
without a micronutrient supplement or placebo for 15 weeks, and then all groups crossed over to active 
treatment for a further 15 weeks. Significant improvements were observed on parent ratings of 
inattention, hyperactivity and impulsivity in both PUFA groups over 15 weeks, which were then 
mirrored in the placebo group after switching to active treatment for 15 weeks. Objective 
improvements were found in children’s ability to switch and control their attention, and on vocabulary 
scores, and these mediated parent-reported improvements in hyperactivity, impulsivity and   
inattention [62]. This study also found that the fatty acid deficiency symptoms used as a selection 
criterion by Stevens et al. [59] improved in both the treatment and placebo groups over 15 weeks, and 
concluded that these symptoms are more likely to be an indicator of n-6 rather than n-3   
deficiency [63]. 
A more recent study was conducted in Sweden with a similar supplement and study design as the 
previous two large trials, but including 75 children aged 8-18 years with ADHD [64]. They did not 
detect significant improvements overall; however, when dividing the sample into subgroups, they 
found that children with the inattentive subtype of ADHD and associated neurodevelopmental 
disorders, i.e. autistic symptoms and learning difficulties, showed similar clinical improvements as the 
previous large studies. 
Therefore, there is evidence that children with ADHD-related symptoms may respond to PUFA 
supplementation and that those with the attention subtype and/or learning difficulties may be more 
likely to respond. Interestingly, studies using a combination of n-3 and n-6 fatty acids have been more 
effective than those with DHA or GLA (DGLA precursor) alone. However, the relative importance of 
EPA, DHA and GLA remain to be determined due to methodological differences between the studies. 
Our group has recently completed a 12 month trial with 7–12 year old children with ADHD in 
Adelaide and Brisbane, Australia, in a 3 x 3 crossover design comparing EPA-rich and DHA-rich oils 
with an LA placebo. At baseline higher DHA was associated with improved reading (although not 
quite significant after controlling for confounders) and higher AA with poorer reading, spelling, 
vocabulary and attention. Interestingly, children with learning difficulties (behind age level on literacy; 
n = 30 with bloods) had lower DHA and total n-3 and higher n-6 PUFA levels, although only the DHA 
relationship remained significant after controlling for differences in age and parent-reported   
health [65]. Preliminary results indicate that, although there were no significant between-group 
differences over 4-months, in children who consented to have blood taken increased erythrocyte DHA 
was associated with improved parent ratings of oppositional behaviour, anxiety/shyness, divided 
attention and reading (n = 45). In the subgroup with learning difficulties (n = 16 with bloods at both 
time points) increased erythrocyte DHA had even stronger associations with improved parent ratings 
of oppositional behaviour, hyperactivity, restlessness/impulsivity, divided attention, reading and 
spelling [66]. These preliminary data indicate that DHA supplementation may be associated with 
improved ADHD symptoms and that children with learning difficulties may be more likely to benefit, Nutrients 2010, 2                                       
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supporting a phospholipid spectrum hypothesis that suggests these symptoms occur on a continuum of 
overlapping and related developmental difficulties [54]. However, the latter sample size was small due 
to difficulties with recruitment/eligibility and need to be investigated further in larger samples. 
Other randomized controlled trials with ADHD and n-3 PUFA are underway in Israel, the UK and 
France, as listed in Table 2. 
3.2. Other Developmental Disorders 
PUFA have also been implicated in other, often related developmental disorders such as autistic 
spectrum disorder [67,68] and dyslexia [69-74]. There is some evidence to suggest that autism may 
involve functional deficiencies or imbalances in n-3 PUFA. Studies on the profiles of PUFA in 
children with autism that have found defects of PUFA and phospholipids, the major constituent of cell 
membranes, have had conflicting results. Vancassel et al. examined plasma phospholipid fatty acids in 
a population of children with autism compared to intellectually disabled controls [75]. They reported a 
23% reduction of DHA levels in the children with autism compared with controls. Reduced RBC 
levels of n-3 PUFA and increased levels of saturated fatty acids (SFA) have also been reported in 
individuals with autism [67,68]. Additionally, there is evidence that n-3 PUFA can assist in 
inflammatory bowel disorders [76], which are often found in children with autism and may play a role 
in its etiology [77]. 
Few studies have investigated effects of n-3 PUFA supplementation in autism. A case report noted 
improvements in symptoms of a boy with autism following EPA supplementation that was increased 
from 1g per day to 3g per day over four weeks, with improvements continuing after an eight-month 
follow-up [78]. An uncontrolled open-label study completed by 18 out of 20 children reported 
significant within-group improvements after three months of combined n-3, n-6 and n-9 PUFA 
supplementation (1g/day) [79]. Only one randomized controlled trial (RCT) trialing n-3 PUFA 
supplementation in autism has been published [80]. This six-week pilot RCT in 13 children with 
autism reported a trend for improvements in hyperactivity and stereotypy in the group receiving n-3 
PUFA. Menhaden fish oil was used with daily doses of 840 mg EPA and 700 mg DHA.  
A three-month crossover RCT was conducted in Durham by Dr Madeleine Portwood, and is yet to 
be published. The daily doses of PUFA used were 558 mg EPA and 174 mg DHA. Results regarding 
outcome measures were inconclusive and postulated to be due to failure to reach a ceiling effect of the 
PUFA over three months. After a one-way crossover, however, improvements were reportedly 
observed after six months of active n-3 PUFA supplementation. Therefore it was concluded that 
further studies examining active versus placebo treatment over six months are warranted. As with 
previous large studies that extended the treatment period in a one-way crossover [60,61], this study 
indicates the importance of the length of supplementation relative to dosage for improvements to be 
observed. Considering the complexity of autism, n-3 PUFA may also be best investigated as an 
adjunctive therapy. Therefore, studies are limited and results are inconclusive. A study is currently 
underway in the US investigating n-3 PUFA for treatment of hyperactivity in children with autism and 
another registered study aiming to investigate n-3 PUFA supplementation in children and adolescents 
with autistic spectrum disorder aimed to complete in 2007 but does not appear to have published 
results (see Table 2). Nutrients 2010, 2                                       
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3.3. Mental Retardation 
To date, fatty acid researchers have not focused specifically on the heterogeneous group of 
disorders that characterize mental retardation. Many people with mental retardation are likely to 
display co-morbid symptoms including hyperactivity, impulsivity, aggression, anxiety, and DSM-IV 
diagnosed psychiatric disorders such as bipolar disorder, schizophrenia [81] and ADHD [82]. It has 
been suggested that the high rate of psychiatric disorders in children and adolescents with mental 
retardation might be a major problem in their functioning and adaptation [83]. The impact of PUFA for 
the amelioration of learning, cognition and behavior control problems in developmental disorders like 
ADHD may have implications for the treatment of these same difficulties in people with mental 
retardation. This is important, particularly given that there are indications that some forms of mental 
retardation might be caused by defects in the structure and functioning of neural synapses [84], which 
are rich in the n-3 PUFA, DHA. For a more in-depth discussion see Sinn and Wilson [85]. 
3.4. Depression and Suicide Ideation 
PUFA deficiency is also implicated in depression. Along with cardiovascular disease (CVD), 
depression seems to be more prevalent in countries where fish consumption is lower, after controlling 
for demographic variables and potentially confounding factors such as alcohol intake [86-90]. It is well 
established that depression often co-occurs with CVD, which is associated with elevated cholesterol 
and lower PUFA levels, and studies have confirmed that depression does not result from CVD as it has 
been found to exist before symptoms of CVD set in [91]. Indicative of a common underlying 
biological component, higher serum AA:EPA ratios were reported in depressed post-myocardial 
infarction patients [92] and lower total n-3 PUFA and DHA levels in depressed patients recovering 
from acute coronary syndromes [93] than in similar patients without depression.  Shared PUFA 
abnormalities might further account for the depression that co-occurs with stress, post-natal 
depression, autoimmune diseases, multiple sclerosis, cancer, diabetes, aging and osteoporosis [91]. A 
number of studies have found lower n-3 PUFA levels or higher AA/EPA ratios in people with 
depression compared with controls [21,94-99], including a postmortem comparison of 15 patients with 
major depressive disorder (MDD) versus 27 controls – specifically lower DHA levels in the frontal  
cortex [100].  
A case study reported improvement in treatment-resistant depression when EPA was added to the 
conventional treatment, which was also associated with reduced neuronal phospholipid turnover and 
structural brain changes over the nine months of treatment [101]. Clinical trials have been previously 
reviewed [41, 102], although new studies have since been published. Six trials used high EPA 
supplements. In a small dose-ranging study, treatment with 1g/day of ethyl-EPA but not 2 or 4g/day 
was effective in improving depressive symptoms in adults with ongoing depression whilst continuing 
their standard medication [103]. However, another small study reported positive treatment effects with 
2g ethyl-EPA as an adjunctive therapy compared with placebo over four weeks [104]. This group also 
conducted a study with 6-12 year old children with major depressive disorder [105]. Only five of the 
twenty children were medicated, and following sixteen weeks of 400mg EPA plus 200mg DHA per 
day, the treatment group showed significant improvements in symptoms on all outcome measures.   Nutrients 2010, 2                                       
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It should be noted that blood samples were not collected in the latter studies. After eight weeks of 
supplementation with  large doses of  n-3 PUFA per day (4.4g EPA, 2.2g DHA) as an adjunctive 
therapy [106], depressed patients in the n-3 PUFA group had significantly lower depression scores 
than the control group (p < 0.001). Importantly, this team did collect blood samples and reported 
average baseline blood DHA levels of 2.5% of fatty acids in the placebo group and 2.4% in the 
treatment group (the latter increased to 5.8% in the DHA group after treatment). According to the 
Omega-3 Index for cardiovascular health the baseline levels correspond with the risk category for 
CVD (EPA + DHA: 4% of total membrane fatty acids) [11] and are therefore indicative of suboptimal 
n-3 PUFA levels. There is some recent evidence that 1 g/day EPA may have similar therapeutic effects 
to 20 mg/day fluoxetine as a treatment for major depression over eight weeks and that using the two 
treatments in combination is superior to either of them alone [107]. A larger recent study (N = 120) 
found no improvements in depressive symptoms following 1.5g ethyl-EPA plus 0.5g ethyl-DHA 
supplementation in middle-aged women with psychological distress over eight weeks [109], although 
they reported improvements in women who did not meet criteria for major depressive episode at 
baseline. A more recent study investigated treatment with 2.2g EPA and 1.2g DHA in Menhaden fish 
oil as a monotherapy for major depressive disorder in pregnant women and found significant 
improvements in the treatment group on all outcome measures compared with placebo [109]. This 
study is interesting because n-3 PUFA are preferentially transported to the growing fetus during 
pregnancy, which can deplete n-3 PUFA levels in pregnant mothers. An uncontrolled study also 
reported reductions in postpartum depression following n-3 PUFA supplementation over eight   
weeks [110]. 
Four studies using DHA or DHA-rich oils did not report improvements following n-3 
supplementation. One of these studies supplemented patients with 2g DHA for only six weeks as a 
monotherapy [111]; one supplied 0.6g EPA + 2.4g DHA as an adjunctive therapy for 12 weeks [112] 
and the largest study gave a similar dosage as an adjunctive therapy for 16 weeks [113]. It should be 
noted though that two of these studies collected blood samples and revealed normal baseline n-3 
levels; Marangell et al. [111] reported that the DHA group and placebo group had 4.15% and 3.78% 
DHA as a percentage of total fatty acids at baseline, respectively, and Grenyer et al. [113] reported 
baseline DHA as 4.2% of total RBC fatty acids. Although in the latter study reductions in depression 
scores did not differ between the groups, both treatment and placebo groups had received counseling, 
which is likely to account for improved mood in the whole sample. Furthermore, these authors later 
reported that increased DHA levels were significantly associated with improvements in depression 
scores [114], warranting further research into DHA and depression. Therefore studies using high EPA 
supplements should also determine to what extent the EPA has been converted to DHA and which of 
these is associated with improvements.  
A larger study investigated depressive symptoms in a cohort of elderly people with mild-moderate 
Alzheimer’s disease who were living in their own homes. This study (cognitive results reported further 
below) found no benefits of treatment on neuropsychiatric symptoms overall, although improved mood 
was detected in the treatment group compared with placebo in non apoE-4 allele carriers and reduced 
agitation in apoE-4 carriers [115]. Given the incidence of depression in Alzheimer’s disease, and 
increased risk of depressed people developing dementia, this merits further investigation. Another Nutrients 2010, 2                                       
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recently published study investigated additive effects of supplementation with ethyl ester EPA and 
DHA on depressive symptoms in conjunction with sertraline in patients with major depression and 
coronary heart disease, finding no benefits of treatment over placebo [116]. 
In one of two further, larger population based studies, Rogers et al. randomized a community 
sample of 190 individuals with mild to moderate depression to a combined EPA + DHA supplement 
(1.5g per day) or olive oil placebo for 12 weeks [117]. They did not report any favourable effects of 
the supplement on depressive symptoms or a range of outcomes and concluded that this supports a 
negligible effect of n-3 on depression. A group from the Netherlands also found no effect of n-3 PUFA 
supplementation on mood in 302 independently living adults [118]. These studies did not use the 
Hamilton Depression Rating Scales (HDRS), which has been generally used as a primary outcome 
measure by the other studies, thereby reducing comparability. Although Rogers et al. took blood 
samples, they measured levels in plasma rather than RBC, and it should be noted that other studies 
reporting improvements in depression scores tended to use inpatients with more severe depression, 
many of whom were treatment resistant. Finally, some studies used a placebo lead-in phase to 
eliminate placebo responders [106], and others used patients who had depression scores indicating 
impaired function despite ongoing treatment with medication [103]. These selection criteria also could 
have influenced the outcomes: eliminating placebo responders may be pertinent to clinical trials in 
depression because often depressive symptoms can lift due to the attention associated with taking part 
in a clinical trial; non-responders to medication may be a subgroup more likely to respond to n-3 
PUFA. Interestingly, Carney et al. did use a two-week placebo lead in phase but did not include non-
responders to medication, and improvements were seen in both treatment and placebo groups, possibly 
in response to the sertraline administered as an adjunctive therapy [116]. 
In summary, 13 randomized controlled trials that investigated effects of n-3 PUFA on depressive 
symptoms were identified, ranging from 4–26 weeks with sample sizes ranging from N = 20–302, in 
wide-ranging populations including psychiatric patients, coronary patients, pregnant women, elderly 
people with Alzheimer’s disease and non-depressed community cohorts, one with children, some as 
adjunctive therapy to existing medication, using variable n-3 PUFA dosages, ratios of EPA:DHA and 
outcome measures. Five studies reported improvements overall, and two in subgroup analyses. Clearly 
more studies are needed with larger sample sizes and attention to selection criteria and likely 
responders, baseline n-3 PUFA levels, erythrocyte blood samples, length of supplementation and 
comparison of EPA vs. DHA-rich oils. A large number of randomized controlled trials are currently 
underway around the world investigating n-3 PUFA in depression, including two US studies that are 
comparing EPA and DHA – see Table 2 for a summary.  
3.5. Bipolar Disorder 
In addition to finding lower DHA levels in the frontal cortex of patients with MDD, McNamara et 
al. also identified lower DHA levels in the postmortem frontal cortex of 18 patients with bipolar 
depression compared with 19 age-matched controls [119]. One of the pioneering intervention trials 
reported on n-3 fatty acids and psychopathology was conducted by Stoll et al. [120] in bipolar disorder 
patients. The placebo-controlled, double-blind clinical trial produced a significantly greater response to 
treatment (64%) in the n-3 PUFA group than in those given olive oil placebos (18.8%). In this study, Nutrients 2010, 2                                       
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patients received fish oil capsules containing a total of 6.2g EPA and 3.4g DHA daily over four 
months, with no adverse effects overall. Since then another five studies have been conducted with 
bipolar patients. An open label study (N = 12) provided 1.5-2g ethyl EPA for 24 weeks as an 
adjunctive therapy [121]. Although there was no control group, at one month 7/10 of these previously 
treatment-resistant patients showed ≥ 50% reduction in HDRS scores and scores in five completers 
were dramatically reduced at six months. The other placebo-controlled studies provided ethyl EPA as 
an adjunctive therapy, supplying 1-2 g for 12 weeks [122] and 6g for 16 weeks [123]. Keck et al. 
reported no improvements in symptoms but Frangou et al. [122] reported significant improvements 
with 1g and 2g/day ethyl EPA over placebo in two out of three outcome measures. None of these 
studies took blood samples.  
Frangou et al. [124] also reported increased brain levels of N-acetyl-aspartate (NAA), a presumed 
marker of neuronal integrity with 2g ethyl-EPA in 14 female outpatients compared with placebo, 
although this was not associated with improvements in symptoms. Treatment with n-3 PUFA in an 
uncontrolled study with a small group of women with bipolar disorder found no significant 
improvement over four weeks but also reported alterations in a marker of membrane fluidity in the n-3 
groups compared with bipolar patients not taking n-3 PUFA and healthy controls [125]. These 
alterations in markers of brain function should be explored further, and perhaps in the context of 
multimodal approaches to treatment. 
Depression and bipolar disorder are often associated with suicidal ideation. The relationship 
between PUFA, increased suicide risk and related disorders is considered in a review by Brunner and 
colleagues [126], who report an association between low cholesterol and higher risk of suicide. A 
recent study investigated n-3 PUFA supplementation, in addition to standard psychiatric care, on 
psychometric measures in adults with recurrent non-fatal self harm [127]. Daily supplementation with 
n-3 PUFA (1.2 g EPA and 0.9 g DHA) for 12 weeks improved psychopathology, specifically scores 
for depression, suicidality and daily stresses, compared with placebo in 49 participants. 
In summary, two controlled studies have improved bipolar symptoms with a large dose combination 
of EPA and DHA over four months and 1-2g/day ethyl-EPA over 12 weeks, and there is some 
evidence from another study that this may impact on suicidal ideation. Again, further investigation of 
supplement formulation and blood analyses of erythrocyte n-3 PUFAs are needed to investigate 
relative efficacy of EPA vs. DHA vs. a combination of the two. Randomized controlled trials in bipolar 
depression are currently underway in Germany and the US (see Table 2). 
Table 2. Registered (unpublished) double-blind randomized placebo-controlled trials of 
omega-3 fatty acids in mental illness.* 
Registrant  Country  Title of study  Date 
registered 
Registration 
number 
Eric Taylor, Child & 
Adolescent Institute of 
Psychiatry 
UK  Omega-3 fatty acid supplementation for 
adolescent boys with ADHD: a double-
blind, randomized controlled trial 
(MAAFA) 
09/05/2006 ISRCTN27741572 Nutrients 2010, 2                                       
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Natalie Sinn; University 
of South Australia & 
Queensland University 
of Technology 
Australia  Randomized controlled trial investigating 
effects of supplementation with omega-3 
fatty acids EPA and DHA versus omega-6 
fatty acid LA on ADHD symptoms and 
learning difficulties in 7-12 year old 
children 
20/06/2007 ACTRN 
012607000332426 
Madeleine Portwood; 
Durham County Council 
UK  The Middlesbrough study: A randomized, 
controlled trial of dietary supplements 
with omega-3/omega-6 fatty acids in 
mainstream school children 
28/09/2007 ISRCTN12286781 
Laboratories URGO  France  A randomized, controlled, double blind 
placebo trial to evaluate the efficacy and 
the tolerance of an omega-3 fatty acids 
supplement in ADHD children 
09/10/2008 NCT00770627 
Hadassah Medical 
Organisation 
Israel The  effect  of omega-3 fatty acid 
supplementation on behavior of children 
with ADHD 
01/04/2009 NCT00874536 
Sherie Novotny; New 
Jersey University of 
Medicine and Dentistry 
USA  Omega-3 fatty acids in the treatment of 
children with autism spectrum disorders 
27/04/2007 NCT00467818 
Stephen Bent; University 
of California 
USA  A randomized, double-blind, placebo-
controlled 12-week study to investigate 
the effect of omega-3 fatty acids on 
hyperactivity in childhood autism 
05/11/2008 NCT00786799 
Atul Singhal, Institute of 
Child Health  
UK  The influence of n-3 fatty acid 
supplementation on vascular and cognitive 
function in healthy young adults; a 
randomized controlled trial 
05/05/2005 ISRCTN19987575 
Lev Gertsik; National 
Center for 
Complementary and 
Alternative Medicine 
USA  PUFA augmentation in treatment of major 
depression 
14/08/2003 NCT00067301 
Maria Makrides; Child 
Nutrition Research 
Centre 
Australia  A randomized trial of DHA in pregnancy 
to prevent postnatal depressive symptoms 
and enhance neurodevelopment in 
children: The DOMInO Trial 
30/09/2005 ACTRN 
12605000569606 
Anne Marie Rees; 
University of New South 
Wales 
Australia A  randomized,  double-blind, placebo 
controlled trial of omega-3 
polyunsaturated fatty acids as a 
monotherapy for major depression 
11/10/2005 NCT00238758 
William Coryell; 
University of Iowa 
USA  Essential fatty acids in management of 
major depressive Disorder – A pilot study 
16/11/2005 NCT00256412 Nutrients 2010, 2                                       
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F Pouwer; VU 
University Medical 
Centre, EMGO-Institute 
Netherlands  Addition of eicosapentaenoic acid to 
maintenance anti-depressant therapy in 
diabetes patients with major depressive 
disorder: a double-blind, placebo-
controlled study 
21/03/2006 NTR624; 
ISRCTN30877831 
Gordon Parker; 
University of New South 
Wales 
Australia A  randomized,  double-blind, placebo 
controlled trial of omega-3 
polyunsaturated fatty acid as an augmenter 
of antidepressant medication for major 
depression 
07/02/2006 NCT00289484 
Vilma Gabbay; National 
Centre for 
Complementary and 
Alternative Medicine 
USA  Omega-3 fatty acids in adolescent 
depression 
07/04/2006 NCT00312897 
David Mischoulon; 
Massachusetts General 
Hospital 
USA Omega-3  fatty  acids  for treatment of major 
depression: Differential effects of EPA 
and DHA, and associated biochemical and 
immune parameters 
04/08/2006 NCT00361374 
Elad Schiff; Bnai Zion 
Medical Center 
Israel  Prevention of depression with omega-3 
fatty acids in chronic carriers of hepatitis 
C treated with interferon alpha 
05/12/2006 NCT00408304 
Robert McNamara; 
University of Cincinnati 
USA  Evaluation of omega-3 fatty acids as a 
treatment-adjunct in adolescent patients 
with major depressive disorder exhibiting 
partial response to SSRI medication: an 
open-label neuroimaging trial
a 
03/08/2007 NCT00511810 
Danit Shahar; Beersheva 
Mental Health Center 
Israel  Folic acid and omega-3 fatty acid 
supplementation in depressed older adults 
– factorial assignment 
28/05/2007 NCT00480207 
Mark Rapaport; National 
Institute of Mental 
Health (NIMH) 
USA Omega-3  fatty  acids  for treatment of major 
depression: Differential effects of EPA 
and DHA, and associated biochemical and 
immune parameters 
14/08/2007 NCT00517036 
Matthew Muldoon; 
University of Pittsburgh 
USA Evaluating  the  effects of omega-3 fatty 
acids on heart disease and behavior; 
Biobehavioral studies of cardiovascular 
disease 
18/04/2008 NCT00663871 
Sayed Naqvi; Cedars-
Sinai Medical Centre 
USA  Omega-3 fatty acids for treatment of 
depression in adolescents 
08/04/2008 NCT00658476 Nutrients 2010, 2                                       
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Alexandra Parker; 
Orygen Youth Health – 
Research Centre 
Australia  The acceptability and effectiveness of a 
combination of problem solving therapy, 
behavioral exercise intervention and 
omega-3 supplements compared to a 
combination of supportive counseling, 
exercise psychoeducation, and placebo 
omega-3 in reducing depression and 
anxiety symptoms in help-seeking young 
people aged 12-25 years: A factorial 
randomized controlled trial 
30/10/2008 ACTRN 
12608000550303 
Geoffrey Schrader, 
Queen Elizabeth 
Hospital; Peter Howe, 
University of South 
Australia 
Australia  Omega-3 fatty acid supplementation for 
symptoms of depression in patients with 
cardiovascular disease 
01/12/2008 ACTRN 
12608000598381 
National Science 
Council 
Taiwan  The effect of fish oil in major depressive 
disorder: a double-blind placebo-
controlled monotherapy trial to 
demonstrate the therapeutic and preventive 
effects of [sic]depression 
31/12/2008 NCT00816322 
Vlima Gabbay; NYU 
School of Medicine 
USA  The role of omega-3 fatty acids in 
adolescent depression 
19/08/2009 NCT00962598 
Krista Lanctôt; 
Sunnybrook Health 
Sciences Centre 
Canada  Treating depression in coronary artery 
disease with omega-3 fatty acids 
(CAROTID) 
10/09/2009 NCT00981383 
National Institute of 
Mental Health (NIMH) 
USA  Omega-3 fatty acids in the treatment of 
major depression and bipolar disorder: A 
double-blind, placebo-controlled trial 
03/11/1999 
(estimated 
completion 
2002) 
NCT00001146 
Andrew Stoll; National 
Center for 
Complementary and 
Alternative Medicine 
USA  Omega-3 fatty acids in bipolar disorder 
prophylaxis 
02/02/2001 
(estimated 
completion 
2004) 
NCT00010868 
Barbara Gracious; 
University of Rochester 
USA  A comparison of omega-3 fatty acids vs. 
placebo in children and adolescents with 
bipolar disorder 
09/11/2005 NCT00252486 
Janet Wozniak; 
Massachusetts General 
Hospital 
USA  A randomized placebo controlled clinical 
trial of omega-3 fatty acid adjunctive to 
open-label aripiprazole for the treatment 
of bipolar disorder in children and 
adolescents ages 6-17 with bipolar 
spectrum disorder 
28/12/2007 NCT00592683 Nutrients 2010, 2                                       
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Sencan Unal; Mayo 
Clinic 
USA  Neurometabolic effects of the essential 
polyunsaturated fatty acids in early-onset 
bipolar disorder: A magnetic resonance 
spectroscopy study 
21/12/2007 NCT00586222 
Emanuel Severus; 
University of Munich 
Germany  Omega-3 fatty acids in bipolar patients 
with a low omega-3 index and reduced 
heart rate variability: The BIPO-3 Trial 
28/04/2009 NCT00891826 
Beth Murphy; Mclean 
Hospital 
USA  A combination of cytidine and omega-3 
fatty acids in bipolar disorder: Are there 
additive or synergistic mood stabilizing 
effects? 
27/02/2009 NCT00854737 
Melissa DelBello, 
Robert McNamara; 
University of Cincinnati 
USA  Neurochemical effects of omega-3 fatty 
acids in adolescents at risk for mania 
08/06/2009 NCT00917501 
Jeffrey Yao; University 
of Pittsburgh 
USA  Coronary artery disease risk in 
schizophrenia: Effect of omega-3 fatty 
acid supplementation 
09/09/2005 NCT00167310 
Havard Bentsen; 
University Hospital, 
Aker 
Norway  A multicentre, placebo-controlled trial of 
eicosapentaenoic acid (EPA) and 
antioxidant supplementation in the 
treatment of schizophrenia and related 
disorders 
05/01/2007 NCT00419146 
Neil Richtand; 
University of Cincinnati 
USA Randomized,  double-blind,  placebo-
controlled pilot trial of essential fatty acid 
deficiency replacement in early 
schizophrenia 
28/12/2007 NCT00585390 
Paul Amminger, Patrick 
McGorry; Orygen 
Research Centre 
Australia, 
Austria, 
China, 
Denmark, 
Germany, 
Switzerland, 
UK 
The NEURAPRO-E (North America, 
EURope, Australia PROdrome) Study: A 
multicenter randomized controlled trial of 
omega-3 fatty acids and cognitive-
behavioral case management for 
symptomatic patients at ultra-high risk for 
early progression to schizophrenia and 
other psychotic disorders to assess the 6-
month transition rate to first episode 
psychosis  
23/09/2008 ACTRN 
12608000475347 
Laure Buydens-
Branchey; National 
Institute on Drug Abuse 
(NIDA) 
USA  Effects of fatty acid supplementation on 
substance dependent individuals 
06/04/2006 NCT00312455 
Miquel Casas; Hospital 
Universitari Vall 
d’Hebron Research 
Institute 
Spain  Efficacy of omega-3 fatty acids on 
borderline personality disorder: A 
randomized, double-blind clinical trial 
16/02/2007 NCT00437099 Nutrients 2010, 2                                       
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John Stein; University of 
Oxford 
UK  Nutrition as a modifiable causal factor in 
anti-social behaviors: A randomized,  
placebo controlled, double blind trial 
(PINUP – PrIson NUtrition Project)  
06/01/2009 ISRCTN41104834 
Joanne Bradbury; 
Blackmores Ltd, 
Southern Cross 
University 
Australia  A pilot randomized controlled double 
blind intervention study of the effects of 
docosahexaenoic acid (DHA)-rich fish oil 
compared with olive oil in psychological 
stress 
20/02/2009 ACTRN 
12609000124235 
Alan Dangour, Medical 
Research Council (UK) 
[179] 
UK  The OPAL Study: Older People And n-3 
Long-chain polyunsaturated fatty acids 
(target sample: 800 people) 
14/07/2004 ISRCTN72331636 
Janet Carter; Department 
of Health; North East 
London Mental Health 
Trust 
UK  A randomized placebo-controlled trial of 
polyunsaturated omega-3 fatty acid in the 
treatment of dementia; a pilot study 
30/09/2005 ISRCTN27372325 
Joseph Quinn; National 
Institute on Aging 
USA  A randomized double-blind placebo-
controlled trial of the effects of 
docosahexaenoic acid (DHA) in slowing 
the progression of Azheimer’s Disease 
22/02/2007 NCT00440050 
Vanessa Danthiir; 
Commonwealth 
Scientific Industrial 
Research Organisation 
(CSIRO) 
Australia  An 18 month study investigating the 
effects of long chain omega-3 
polyunsaturated fatty acids 
supplementation on cognition and 
wellbeing in older people (EPOCH) 
24/05/2007 ACTRN 
12607000278437 
Bruno Vellas; Toulouse 
University Hospital 
[180] 
France Assessment  of  the efficacy of omega-3 
fatty acids supplementation, multi-domain 
intervention or their combination on the 
change of cognitive functions in frail 
elderly subjects 
02/05/2008 NCT00672685 
Natalie Sinn; University 
of South Australia 
Australia  Effects of omega-3 fatty acids high in 
eicosapentaenoic acid (EPA) or 
docosahexaenoic acid (DHA) versus 
placebo on cognition and mood in older 
adults with mild cognitive impairment 
03/04/2009 ACTRN 
12609000167268 
Katia Tanaka; 
Universidade Federal de 
Sao Paulo 
Brazil  A randomized controlled trial evaluating 
the effects of the association of ginkgo 
biloba, omega-3 and physical exercise in 
memory and executive functions of older 
people with Parkinson’s disease 
22/07/2009 ACTRN 
12609000609257 
Christine Marx, Durham 
VA Medical Centre 
USA  Omega-3 fatty acids and post traumatic 
stress disorder 
20/03/2008 NCT00644423 Nutrients 2010, 2                                       
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Yutaka Mastuoka; Japan 
Science and Technology 
Agency 
Japan  Phase 2 study of Tachikawa Project for 
Prevention of Post-traumatic stress 
disorder with polyunsaturated fatty acid: 
TPOP-01 Study 
23/04/2008 NCT00671489 
Yutaka Mastuoka; Japan 
Science and Technology 
Agency 
Japan Tachikawa  Project  for Prevention of Post-
traumatic stress disorder with 
polyunsaturated fatty acid: TPOP-02 
Study  
01/05/2008 NCT00671099 
 
Trials are grouped according to subheadings in main text (e.g., ADHD, depression, etc.), apart from 
three new studies in post-traumatic stress disorder. All trial identification numbers were searched in 
PubMed to check if they had been published yet. *Located on the World Health Organization’s 
International Clinical Trials Registry Platform Search Portal (http://apps.who.int/trialsearch/)–search 
terms ‘omega-3’ or ‘n-3 fatty acids’. 
aThis trial was open label and uncontrolled but was included in 
the table because of physiological assessment of neurological changes in response to omega-3 
supplementation 
3.6. Schizophrenia 
There are a number of indications that phospholipid abnormalities may explain biological 
underpinnings of schizophrenia [26,128-131]. Low n-3 fatty acid levels in diets or RBC have 
consistently been found in people with schizophrenic symptoms compared to controls [132-136]. 
Clinical trials with schizophrenia have reported mostly positive results. In an apparently open-label 
trial with 20 schizophrenic patients, significant improvements in symptoms were reported after daily 
supplementation with 10g fish oil over six weeks, and improvements were reported to correlate with 
increased n-3 PUFA blood levels [137]. Four double-blind controlled trials with EPA supplementation 
have produced some significant, positive outcomes [138-140] although in Peet et al. 2002 [140] only 
with 2g (vs. 1 and 4g) ethyl-EPA per day in the subgroup of patients taking clozapine and 
improvements were also associated with increased levels of AA.  
Another trial found no differences between schizophrenic patients given ethyl EPA and those given 
placebo over 16 weeks [141]. Horrobin [142] proposed a number of reasons why an effect might not 
have been obtained, including the possibility that ethyl EPA may not have therapeutic benefits. 
Hibbeln et al. [143] investigated possible confounding variables using the same data set, and found 
that PUFA status in schizophrenic patients was predicted by smoking status, gender, and dietary intake 
of n-3 fatty acids. They concluded that phospholipid abnormalities may be an artefact of these 
variables. However, Emsley et al. [138] found significant differences between active and placebo 
groups on the Positive and Negative Syndrome Scale after controlling for age, gender, length of illness 
and dietary n-3 intake; further analyses revealed that these improvements were accounted for by 
improved dyskinesia. 
In another recent study [132], schizophrenic patients were matched with healthy controls on a 
number of factors known to influence PUFA status including age, gender, dietary patterns, smoking Nutrients 2010, 2                                       
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and substance abuse. Schizophrenic patients still had significantly lower levels of EPA and DHA, and 
higher levels of AA than controls. They then gave patients in their study a combination of EPA, DHA 
and antioxidants (Vitamins E and C) over four months; there was no placebo group. The researchers 
reported significant within-group improvements on various measures of psychopathology between pre- 
and post-treatment, which continued for four months after the treatment was discontinued. These 
results need to be interpreted with caution given equivalent placebo to treatment effects found in other 
trials of both depression and schizophrenia. Two more recently published studies  focused on first-
episode psychosis. The first study was with young adults who were provided 2g/day of ethyl-EPA or 
placebo along with psychotic medication (the majority had been previously unmedicated) [144]. Initial 
analyses found no treatment effects over 12 weeks; however did find improvements in patients with 
non-affective psychosis and in those who had had longer duration of untreated psychosis. Treatment 
effects were significant at 4-6 weeks then matched the placebo group at 12 weeks, indicating that the 
ethyl-EPA may have improved response to psychotic medication and/or the effects of the medication 
matched the ethyl-EPA by 12 weeks. The second study aimed to investigate whether 1.3g/day n-3 
PUFA supplementation over 12 weeks could reduce the transition of sub-threshold psychosis to first-
episode psychotic disorder in adolescents and young adults over 12 months [145]. There was a 
significantly reduced transition to psychosis in the treatment group (2/41) compared with the placebo 
group (11/40). A couple of further trials in schizophrenia, one a multicentre intervention involving the 
latter research group, are currently underway (see Table 2). 
3.7. Stress, Aggression, Hostility, Impulsivity, Criminal and Antisocial Behavior  
A number of studies have indicated a biological basis for aggression and criminal-related behaviour. 
Low concentrations of cerebrospinal fluid 5-hydroxyindoleacetic acid (CSF 5-HIAA), a marker of 
cerebral serotonin turnover, have consistently been associated with impulsive, violent, suicidal, hostile 
and aggressive behaviors, as well as early onset of alcohol dependence and personality disorders 
[31,146]. Low PUFA status has also been associated with deficient serotonergic neurotransmission 
[28,29] and it is possible that low CSF 5-HIAA reflects this deficiency.  
A small number of clinical trials have investigated the impact of PUFA supplementation on 
aggressive behaviour. A double-blind, placebo-controlled study measured effects of daily 
supplementation with oil containing 49.3% (1.5g) DHA, 6.7% EPA, 7.3% oleic acid, 3.3% AA and 
other oils for three months on cognitive outcomes and aggression in a group of 41 healthy Japanese 
students from two universities [147]. The placebo capsules contained small amounts of LA and ALA. 
No differences between groups were observed on cognitive tests of executive function, but a 
significant difference was reported in aggression towards others (‘extraggression’) at the end of the 
study, during a highly stressful final exam period. Extraggression scores significantly increased in the 
control groups and decreased (though not significantly) in the DHA supplemented groups. Serum 
blood analyses confirmed a significant increase in EPA and DHA levels in the treatment groups. 
Therefore three months’ supplementation with n-3 PUFA seemed to assist students in controlling 
aggression towards others on a psychological test during a period of high stress. Drawing from 
research on stress-induced hostility and aggression, an Australian group investigated a possible Nutrients 2010, 2                                       
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adaptive role of DHA in perceived stress levels of university staff, finding no differences between 
treatment and placebo but positive effects in the treatment compared with a control group [148]. 
Another double-blind study tested effects of supplementation with 1g ethyl-EPA daily or placebo 
over eight weeks on moderate borderline personality disorder, characterized by emotional reactivity 
and impulsive aggression, in a group of women [149]. The treatment group had a significantly greater 
decrease in depression and aggression scores at the end of the study.  
A landmark randomized, placebo-controlled trial was undertaken with 231 young adult prisoners to 
investigate effects of supplementation with micronutrients and essential fatty acids over four-five 
months on antisocial behavior [150]. The participants were given multi-vitamin/mineral capsules and 
fatty acid supplement providing n-3 and n-6 fatty acids (1260mg LA, 160mg GLA, 80mg EPA and 
44mg DHA daily) or placebo. During the trial, the treatment group received significantly fewer 
disciplinary actions, and the greatest effect was noted for violent behavior. These studies add an 
important dimension to research with PUFA in ADHD, which is commonly associated with antisocial 
behavior symptomatic of conduct disorder and oppositional defiant disorder in childhood [151-153] 
and criminality and antisocial behavior in late adolescence and adulthood [154,155]. This work is 
currently being continued on a large scale with prisons in the UK, investigating effects of 
micronutrients and PUFA on anti-social behaviour in a randomized controlled trial over 4 months 
(‘PINUP’; see Table 2). 
Recently, a small randomized controlled trial in 24 men with substance abuse found that 
supplementation with 3g/day of n-3 PUFAs for three months improved self-reported scores of anger 
and anxiety compared to a soybean oil placebo [156]. The active group received five capsules per day 
each containing 450 mg of EPA, 100 mg of DHA and 50 mg of n-3 PUFAs ALA and DPA. Although 
five participants in both the placebo and active groups were on antidepressant medication during the 
study, their doses remained stable. Interestingly, the anger ratings remained lower in the active group 
for three months after supplementation ceased. Each participant’s n-3 PUFA intake was calculated 
from a diet questionnaire covering the month preceding the study and it was reported that the 
participants had a daily intake of 148mg LC n-3 PUFAs, only 30% of the ISSFAL recommended 
intake of 500 mg/day. Furthermore, those participants who reported a history of violent behaviour had 
a significantly lower LC n-3 PUFA intake compared to those who had no history of this behaviour. 
After the 3 month treatment with LC n-3 PUFAs, a low anxiety score was associated with an increase 
in EPA but not DHA, whereas a low anger score was associated more strongly with DHA. This 
indicates possible variation between the two LC n-3 PUFAs in their effect on psychiatric conditions 
and warrants comparison of them in further research.  
A randomized controlled trial is currently investigating the role of n-3 PUFA in alleviating 
psychological stress in university students undertaking exams, and another study in Spain is assessing 
n-3 PUFA supplementation for symptoms of borderline personality disorder (Table 2). 
3.8. Dementia and Alzheimer’s Disease 
Free radical activity and phospholipid membrane degeneration have been associated with 
neurodegenerative disorders. With aging, neural membrane fluidity is generally compromised due to 
an increase in cholesterol, reduced activity level of desaturase enzymes, impaired phospholipid Nutrients 2010, 2                                       
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metabolism and increased oxidative stress [20]. Such derangements may be associated with dementia 
and Alzheimer’s Disease (AD), e.g., autopsied brains of patients who suffered AD showed 
significantly higher saturated fat and lower PUFA content, particularly DHA, in the hippocampus and 
frontal lobes compared to aged controls [157], which is consistent with reports of decreased 
hippocampus size and function in AD patients [20].  
Prospective cohort/population studies have indicated that higher fish consumption is 
associated with reduced risk of dementia/AD [158-165]. A single case report of an elderly dementia 
patient noted clinical improvement over several months of increased fish consumption, which led the 
author to hypothesise that n-3 PUFA contributed to his improved functioning, although it could have 
been attributed to numerous other factors associated with admittance to a nursing home [166]. 
Investigation of n-3 PUFA status in AD patients did find significantly reduced EPA and DHA levels 
compared to controls, particularly DHA levels which were consistently less than half those in the 
control group [167].  
Relatively few controlled studies have investigated effects of n-3 PUFA supplementation on 
dementia to date. In a short four-week double blind trial with 100 AD patients, a number of 
improvements in symptoms were reported in 49 of the 60 patients who received an n-3/n-6 supplement 
comprising 0.5g of ALA and LA in a 1:4 ratio [168].  
Supplementation with 4.32g DHA daily for one year improved dementia scores of 10 elderly 
volunteers with vascular dementia compared with 10 controls who did not receive capsules [169]. 
Another pilot study in 19 participants with mild to moderate AD treated with 1g/day ethyl-EPA for 12 
weeks showed no improvement in cognitive functioning, possibly due to the short period of 
supplementation and/or the nature of the supplement formulation [170]. Supplementation with 
240mg/day of DHA and AA improved immediate memory and attention in 12 adults with mild 
cognitive impairment (MCI) but not eight adults with AD compared to an olive oil MCI placebo  
group [171]. In the largest study to date with 174 volunteers with diagnosed AD, only those with very 
mild AD (n = 27) showed reductions in cognitive decline after adjunctive supplementation with 1700 
mg/day DHA and 600 mg/day EPA for six months and the placebo group improved after switching to 
n-3 PUFA for a further 6 months [172]. Similarly, a study recently published online also reported 
improvements relative to placebo in MCI but not AD patients following supplementation with 
1.8g/day n-3 PUFA (1080mg EPA, 720mg DHA) over 24 weeks [173]. One population based study 
investigated the effect of DHA and EPA on cognitive performance of 302 elderly people > 65 years 
without dementia and detected no treatment effects over 26 weeks, although it did report 
improvements in attention in apoE-4 carriers and males [174]. The prior studies indicate that early 
stages of cognitive decline may be optimal for intervention with n-3 PUFA. MCI is considered a risk 
factor for AD, with an estimated 16-41% of people with MCI converting to a diagnosis of AD each 
year and up to 64% after two years. It has been suggested therefore that MCI is possibly the earliest 
stage of detectable AD [175]. Furthermore, major and minor depression often co-occur in MCI [176] 
and increase the risk of progressing to AD [177].  
Further investigation of the role of PUFA in dementia is needed, focusing on larger sample sizes, 
the nature of the supplement (e.g., EPA versus DHA), dosage, length of supplementation, baseline 
RBC n-3 PUFA proportions, response in ApoE ε4 allele carriers, longer-term outcomes and Nutrients 2010, 2                                       
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therapeutic implications. Finally, cardiovascular risk factors for AD have led to recent suggestions that 
lifestyle factors such as inadequate physical activity and/or n-3 PUFA intake may contribute to 
reduced cerebral blood flow and blood-brain barrier integrity [37], supporting the notion that one of 
the primary functions of n-3 PUFA on mental health may be improved circulatory function [36]. This 
should also be explored in future research. 
We are currently collecting data for a six-month study comparing EPA with DHA-rich supplements 
versus an LA placebo on mood and cognition in elderly people with MCI. Other controlled trials are 
underway to assess n-3 PUFA supplementation and cognition in healthy older adults and those with 
dementia (see Table 2 for details). 
4. Conclusions  
There is growing evidence that suboptimal intakes of n-3 PUFA may be associated with 
psychopathology over the lifespan and include highly prevalent disorders that present a growing public 
health concern. Most clinical trials have been conducted with major depressive illness in adulthood and 
in childhood disorders; there are growing numbers of interventions with cognitive decline in older 
adulthood. Although the causes of these mental health problems are complex and multifactorial, even 
from a nutritional perspective alone [e.g., 40, 178], dietary and lifestyle factors including n-3 PUFA 
present modifiable risk factors that can be accessed relatively easily by individuals.  
However, findings of clinical trials have been inconsistent and in many cases inconclusive; 
methodological differences between studies need to be critically evaluated before drawing conclusions 
about the efficacy or otherwise of n-3 PUFA in alleviating symptoms. These include sample size, 
selection criteria, the dosage of the supplement, the nature of the fatty acids (i.e. EPA- or DHA-rich or 
combined oil; inclusion of n-6 PUFA), and length of supplementation. Given the widespread use of 
ethyl-esthers, short- and long-term investigation of bioavailability compared with naturally occurring 
fatty acids in fish oil is warranted. The role of n-6 PUFA also needs to be clarified as some studies 
found improved and some worse outcomes associated with AA, and successful studies with children 
included evening primrose oil in the treatment. Some studies in depression have included inpatients 
with clinical depression despite ongoing medication. Non-responders to other treatments are a possible 
future area of attention for n-3 PUFA and/or micronutrient supplementation because suboptimal 
nutrient levels may explain this lack of response to other treatments. Some depression studies have 
conducted a placebo-lead in phase to eliminate placebo responders and this may also assist in 
clarifying true treatment effects. Importantly, studies need to identify baseline n-3 PUFA levels in 
erythrocyte membranes because this may be a major contributor to different findings between studies. 
This will also assist researchers and clinicians in identifying likely responders.  
Outcome measures also need consideration; as can be seen in Table 1, a great variety of 
psychological/cognitive outcome measures have been used across these studies and their sensitivity to 
detecting effects of n-3 PUFA supplementation is varied. Of particular interest are two large studies in 
the UK [60, 150]. In most studies with children, parent and teachers have reported improvements; 
however cognitive assessments detected varied (mostly no) improvements. In the Durham trial [60], 
reading and spelling were included as outcome measures with highly significant, and meaningful, 
improvements in these literacy indicators. In the prison-based trial with criminal offenders [150], a Nutrients 2010, 2                                       
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range of psychological assessments were used that did not detect any response to micronutrient/n-3 
PUFA supplementation; however prison disciplinary actions were recorded in the treatment and 
placebo groups and detected significantly less reprimands in the treatment group, particularly in 
violent behaviour. Therefore selection of outcome measures is an area in serious need of attention. 
Finally, only one study appears to have conducted a follow-up; four months after treatment ceased, 
anger levels remained low [156]; whether this was due to retention of n-3 PUFA in cell membranes or 
a result of newly learned behavioral changes remains to be determined and also needs to be 
investigated by future researchers. In conclusion, as well as identifying likely responders, future 
research investigating effects of n-3 PUFA supplementation on mental health and behavior needs to 
define meaningful and long term outcomes and optimal supplementation strategies including 
combinations with other lifestyle risk factors and nutrients that are consumed suboptimally.  
 
Notes added in proof 
 
After writing this review another study was identified by a group in Israel (Raz et al., 2009). They 
published a randomised controlled trial with 7-13 year old unmedicated children with ADHD that 
reported no treatment effects on parent and teacher questionnaires or a computerised continuous 
performance task. However the PUFA supplement contained relatively small amounts of LA (480mg) 
and ALA (120mg), the latter of which is likely to have had minimal conversion to EPA and DHA, and 
they were only supplemented for 7 weeks, whereas at least 8 and preferably a minimum of 12 weeks 
tend to be required to show any improvements overall, and with larger doses of long-chain n-3 PUFAs. 
Interestingly they did report some improvements in both groups which could be a placebo effect 
although the placebo contained vitamin C and was therefore not a non-active compound. 
Raz, R.; Carasso, R. L.; Yehuda, S. The Influence of Short-Chain Essential Fatty Acids on Children 
with Attention-Deficit/Hyperactivity Disorder: A Double-Blind Placebo-Controlled Study. J Child 
Adolesc Psychopharmaco, 2009, 19, 167-177. 
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